GÜTERSLOH, Germany, December 8 /PRNewswire/ -- LYCOS Europe introduces STRATO a strong European Webhosting provider, as its exclusive partner for LYCOS Webhosting customers who based on the current situation would like to re-orientate themselves.

STRATO and LYCOS are currently focusing on the transferring of domains which will guarantee in making the transition as easy as possible.

In addition STRATO are offering free of charge a Hotline, Online-Chat and Call-back service for any queries that might arise.

More information relating this partnership will be released mid December. The LYCOS Webhosting branch will still be operating during the first quarter of 2009.

HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple studies at the 2008 San Antonio Breast Cancer Symposium (SABCS) and Agendia will support, with an unrestricted grant, the New Frontiers in Individualized Breast Cancer Therapy symposium. The San Antonio Breast Cancer Symposium, one of the premiere conferences in breast cancer research worldwide, takes place December 10th-14th, 2008.

REYKJAVIK, Iceland, December 8 /PRNewswire/ --

deCODE genetics (Nasdaq: DCGN) today announced the discovery by an international consortium of scientists from deCODE and major European and US academic institutions of a single letter variation in the human genome (SNP) that is associated with increased fasting glucose levels and risk of type 2 diabetes (T2D). deCODE will employ its CLIA-registered genotyping laboratory and existing testing platform to swiftly integrate the finding into its deCODEme(TM) personal genome scan, and to assess the addition of this new variant to the company's deCODE T2(TM) reference laboratory test for assessing individual risk of type 2 diabetes.

ZURICH, Switzerland, December 8 /PRNewswire/ --

- Breakthrough Home Use Study Finalised

- Board of Directors Reinforced

Solianis has just finalised a test series in which patients with diabetes have worn the first configuration of the multisensor system for non-invasive Continuous Glucose Monitoring at home and at work. Results show that the system tracks glucose in these settings and that it is sensitive to hyper- and hypoglycemic glucose excursions.

SAN JOSE, California, December 8 /PRNewswire/ --

Super Micro Computer, Inc. (Nasdaq: SMCI), a leader in application-optimized, high performance server solutions, today announced that the channel has ranked Supermicro as the number one x86 server vendor over HP, IBM, Dell, Sun, Apple and Gateway. As published in the November 24th issue of CRN (Channel Reseller News), the 2008 Channel Affinity Index, which is based on the result of 8,000 survey responses conducted with solutions providers, ranks Supermicro as the top x86 server vendor.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081208/AQM062)

PORTO, Portugal, December 8 /PRNewswire/ --

- Data Highlight The Efficacy, Safety and Significant Improvement in Quality of Life and Depressive Symptoms With Zebinix(TM) (Eslicarbazepine Acetate)

Positive data from three phase III studies presented today at the American Epilepsy Society (AES) Congress, Seattle, USA, show that Zebinix(TM)(1) (eslicarbazepine acetate), a novel once-daily anti-epileptic agent, significantly reduced the frequency of partial seizures and has the potential to significantly improve quality of life and depressive symptoms in patients with partial refractory epilepsy, in combination with other anti-epileptic agents.(2),(3),(4)

Zebinix(TM) is one of the proposed EU trade names for eslicarbazepine acetate.

AMSTERDAM, December 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc(TM) Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc(TM) is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.

This is an important strategic milestone in the development of Reviroc(TM) and we are very pleased with the orphan drug designations received from the FDA, says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

LONDON, December 8 /PRNewswire/ --

- First Small Luxury Hotels of the World property in Europe to install two-way interface to SLH's Central Reservation System

MICROS-Fidelio UK Ltd, a wholly-owned subsidiary of MICROS Systems, Inc. (Nasdaq: MCRS), a leading provider of information technology solutions for the hospitality and retail industries, is pleased to announce that The Atlantic Hotel is the first Small Luxury Hotels of the World (SLH) property in Europe to deploy MICROS's OPERA Xpress Property Management System (PMS).

MORRIS TOWNSHIP, New Jersey, December 8 /PRNewswire/ --

- SAE's International Cooperative Research Program finds new refrigerant offers 'superior environmental performance'

Honeywell (NYSE: HON) announced today that the SAE International Cooperative Research Program has endorsed Honeywell's low-global-warming-potential refrigerant for use in mobile air conditioning (MAC) to meet new, more stringent regulations in Europe.

The SAE program team said refrigerant HFO-1234yf offers superior environmental performance and that this alternative refrigerant -- of all proposed alternatives -- has been judged to have the lowest risk for use in mobile air conditioning systems in meeting environmental and consumer needs.

EAST GREENBUSH, New York, December 8 /PRNewswire/ --

- Company's open API and 'Ready for Autotask' program proven to integrate seamlessly with the business applications and managed services platforms Autotask customers rely on most

Autotask Corporation today announced it is leading the PSA industry in successful technology integrations and using its open API and Ready for Autotask program to actively engage IT-focused vendors and manufacturers and simplify the integration and interoperability process.

Autotask CEO Bob Godgart says it is these technology alliances that really differentiate and strengthen the company's central role within the IT services ecosystem and help its customers to grow their services business faster and more effectively.